Lifeward (LFWD) Competitors

$6.70 +0.11 (+1.67%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$6.80 +0.11 (+1.57%)

As of 05/15/2026 06:43 PM Eastern

LFWD vs. PSTV, CTSO, POCI, STRR, and NMTC

Should you buy Lifeward stock or one of its competitors? MarketBeat compares Lifeward with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lifeward include Plus Therapeutics (PSTV), Cytosorbents (CTSO), Precision Optics (POCI), Star Equity (STRR), and NeuroOne Medical Technologies (NMTC). These companies are all part of the "medical equipment" industry.

How does Lifeward compare to Plus Therapeutics?

Lifeward (NASDAQ:LFWD) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

Lifeward has higher revenue and earnings than Plus Therapeutics. Lifeward is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifeward	$22.03M	0.47	-$19.91M	-$18.49	N/A
Plus Therapeutics	$5.21M	6.91	-$22.39M	-$31.00	N/A

Lifeward presently has a consensus target price of $10.00, suggesting a potential upside of 49.25%. Plus Therapeutics has a consensus target price of $58.00, suggesting a potential upside of 1,004.76%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Plus Therapeutics is more favorable than Lifeward.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifeward	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Lifeward has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market.

In the previous week, Lifeward had 2 more articles in the media than Plus Therapeutics. MarketBeat recorded 8 mentions for Lifeward and 6 mentions for Plus Therapeutics. Plus Therapeutics' average media sentiment score of 0.02 beat Lifeward's score of -0.14 indicating that Plus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifeward	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Plus Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

26.8% of Lifeward shares are held by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are held by institutional investors. 1.5% of Lifeward shares are held by insiders. Comparatively, 2.5% of Plus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Lifeward has a net margin of -90.38% compared to Plus Therapeutics' net margin of -429.43%. Plus Therapeutics' return on equity of 0.00% beat Lifeward's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifeward	-90.38%	-145.55%	-78.36%
Plus Therapeutics	-429.43%	N/A	-92.28%

Summary

Plus Therapeutics beats Lifeward on 9 of the 16 factors compared between the two stocks.

How does Lifeward compare to Cytosorbents?

Lifeward (NASDAQ:LFWD) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Cytosorbents has higher revenue and earnings than Lifeward. Cytosorbents is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifeward	$22.03M	0.47	-$19.91M	-$18.49	N/A
Cytosorbents	$37.20M	0.84	-$8.20M	-$0.19	N/A

Lifeward presently has a consensus target price of $10.00, suggesting a potential upside of 49.25%. Cytosorbents has a consensus target price of $5.38, suggesting a potential upside of 980.18%. Given Cytosorbents' higher possible upside, analysts clearly believe Cytosorbents is more favorable than Lifeward.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifeward	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Lifeward has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market. Comparatively, Cytosorbents has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market.

In the previous week, Cytosorbents had 3 more articles in the media than Lifeward. MarketBeat recorded 11 mentions for Cytosorbents and 8 mentions for Lifeward. Cytosorbents' average media sentiment score of -0.14 beat Lifeward's score of -0.14 indicating that Cytosorbents is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifeward	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytosorbents	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

26.8% of Lifeward shares are held by institutional investors. Comparatively, 32.9% of Cytosorbents shares are held by institutional investors. 1.5% of Lifeward shares are held by insiders. Comparatively, 7.3% of Cytosorbents shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cytosorbents has a net margin of -31.85% compared to Lifeward's net margin of -90.38%. Lifeward's return on equity of -145.55% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifeward	-90.38%	-145.55%	-78.36%
Cytosorbents	-31.85%	-235.57%	-37.88%

Summary

Cytosorbents beats Lifeward on 12 of the 14 factors compared between the two stocks.

How does Lifeward compare to Precision Optics?

Lifeward (NASDAQ:LFWD) and Precision Optics (NASDAQ:POCI) are both small-cap medical equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Precision Optics has a net margin of -17.03% compared to Lifeward's net margin of -90.38%. Precision Optics' return on equity of -37.47% beat Lifeward's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifeward	-90.38%	-145.55%	-78.36%
Precision Optics	-17.03%	-37.47%	-19.96%

26.8% of Lifeward shares are held by institutional investors. Comparatively, 13.7% of Precision Optics shares are held by institutional investors. 1.5% of Lifeward shares are held by insiders. Comparatively, 14.4% of Precision Optics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Precision Optics has higher revenue and earnings than Lifeward. Precision Optics is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifeward	$22.03M	0.47	-$19.91M	-$18.49	N/A
Precision Optics	$28.94M	1.27	-$5.78M	-$0.63	N/A

Lifeward has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market. Comparatively, Precision Optics has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market.

Lifeward presently has a consensus target price of $10.00, suggesting a potential upside of 49.25%. Given Lifeward's stronger consensus rating and higher possible upside, analysts clearly believe Lifeward is more favorable than Precision Optics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifeward	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Precision Optics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Precision Optics had 2 more articles in the media than Lifeward. MarketBeat recorded 10 mentions for Precision Optics and 8 mentions for Lifeward. Precision Optics' average media sentiment score of 0.15 beat Lifeward's score of -0.14 indicating that Precision Optics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifeward	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Precision Optics	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Precision Optics beats Lifeward on 10 of the 16 factors compared between the two stocks.

How does Lifeward compare to Star Equity?

Lifeward (NASDAQ:LFWD) and Star Equity (NASDAQ:STRR) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

26.8% of Lifeward shares are held by institutional investors. Comparatively, 3.8% of Star Equity shares are held by institutional investors. 1.5% of Lifeward shares are held by company insiders. Comparatively, 33.5% of Star Equity shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Star Equity had 12 more articles in the media than Lifeward. MarketBeat recorded 20 mentions for Star Equity and 8 mentions for Lifeward. Star Equity's average media sentiment score of -0.07 beat Lifeward's score of -0.14 indicating that Star Equity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifeward	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Star Equity	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lifeward presently has a consensus target price of $10.00, suggesting a potential upside of 49.25%. Star Equity has a consensus target price of $28.00, suggesting a potential upside of 187.77%. Given Star Equity's stronger consensus rating and higher probable upside, analysts clearly believe Star Equity is more favorable than Lifeward.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifeward	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Star Equity	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

Lifeward has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market. Comparatively, Star Equity has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market.

Star Equity has a net margin of -4.18% compared to Lifeward's net margin of -90.38%. Star Equity's return on equity of -4.04% beat Lifeward's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifeward	-90.38%	-145.55%	-78.36%
Star Equity	-4.18%	-4.04%	-2.40%

Star Equity has higher revenue and earnings than Lifeward. Star Equity is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifeward	$22.03M	0.47	-$19.91M	-$18.49	N/A
Star Equity	$172.16M	0.21	-$5.92M	-$2.63	N/A

Summary

Star Equity beats Lifeward on 13 of the 16 factors compared between the two stocks.

How does Lifeward compare to NeuroOne Medical Technologies?

NeuroOne Medical Technologies (NASDAQ:NMTC) and Lifeward (NASDAQ:LFWD) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. Comparatively, 26.8% of Lifeward shares are owned by institutional investors. 11.8% of NeuroOne Medical Technologies shares are owned by company insiders. Comparatively, 1.5% of Lifeward shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Lifeward had 1 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 8 mentions for Lifeward and 7 mentions for NeuroOne Medical Technologies. NeuroOne Medical Technologies' average media sentiment score of 0.20 beat Lifeward's score of -0.14 indicating that NeuroOne Medical Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroOne Medical Technologies	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lifeward	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NeuroOne Medical Technologies has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market. Comparatively, Lifeward has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market.

NeuroOne Medical Technologies currently has a consensus target price of $11.67, indicating a potential upside of 177.12%. Lifeward has a consensus target price of $10.00, indicating a potential upside of 49.25%. Given NeuroOne Medical Technologies' stronger consensus rating and higher possible upside, analysts clearly believe NeuroOne Medical Technologies is more favorable than Lifeward.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Lifeward	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

NeuroOne Medical Technologies has a net margin of -68.35% compared to Lifeward's net margin of -90.38%. NeuroOne Medical Technologies' return on equity of -98.33% beat Lifeward's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroOne Medical Technologies	-68.35%	-98.33%	-69.85%
Lifeward	-90.38%	-145.55%	-78.36%

NeuroOne Medical Technologies has higher earnings, but lower revenue than Lifeward. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroOne Medical Technologies	$12.10M	3.00	-$3.61M	-$0.85	N/A
Lifeward	$22.03M	0.47	-$19.91M	-$18.49	N/A

Summary

NeuroOne Medical Technologies beats Lifeward on 12 of the 16 factors compared between the two stocks.

Get Lifeward News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LFWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LFWD vs. The Competition

Export

Metric	Lifeward	INTERNET SOFTWARE Industry	Computer Sector	NASDAQ Exchange
Market Cap	$10.08M	$16.50B	$39.62B	$12.47B
Dividend Yield	N/A	4.90%	3.20%	5.25%
P/E Ratio	-0.36	60.99	165.38	25.23
Price / Sales	0.47	38.45	634.31	82.40
Price / Cash	N/A	64.53	48.70	56.04
Price / Book	1.21	8.78	10.26	6.90
Net Income	-$19.91M	$379.18M	$1.03B	$334.44M
7 Day Performance	6.35%	-4.25%	-1.47%	0.16%
1 Month Performance	0.30%	-0.30%	5.43%	1.15%
1 Year Performance	-57.05%	-9.58%	161.28%	30.63%

Lifeward Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LFWD Lifeward	1.8341 of 5 stars	$6.70 +1.7%	$10.00 +49.3%	-56.7%	$10.08M	$22.03M	N/A	60	News Coverage Earnings Report
PSTV Plus Therapeutics	2.6024 of 5 stars	$5.99 -3.8%	$58.00 +869.1%	-58.5%	$41.28M	$5.21M	N/A	20	News Coverage Earnings Report Gap Down
CTSO Cytosorbents	1.84 of 5 stars	$0.62 +1.6%	$5.38 +774.0%	-40.4%	$38.56M	$37.06M	N/A	220	News Coverage Earnings Report Analyst Revision Gap Down
POCI Precision Optics	0.4102 of 5 stars	$4.72 +11.5%	N/A	+0.0%	$37.30M	$19.09M	N/A	80	News Coverage Earnings Report Gap Up
STRR Star Equity	4.3745 of 5 stars	$9.52 -0.5%	$16.50 +73.3%	+314.0%	$35.36M	$172.16M	N/A	1,200	Trending News Earnings Report Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LFWD) was last updated on 5/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lifeward (LFWD) Competitors

LFWD vs. PSTV, CTSO, POCI, STRR, and NMTC

How does Lifeward compare to Plus Therapeutics?

Summary

How does Lifeward compare to Cytosorbents?

Summary

How does Lifeward compare to Precision Optics?

Summary

How does Lifeward compare to Star Equity?

Summary

How does Lifeward compare to NeuroOne Medical Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFWD vs. The Competition

Lifeward Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lifeward (LFWD) Competitors

LFWD vs. PSTV, CTSO, POCI, STRR, and NMTC

How does Lifeward compare to Plus Therapeutics?

Which has better valuation and earnings, LFWD or PSTV?

Do analysts prefer LFWD or PSTV?

Which has more volatility and risk, LFWD or PSTV?

Does the media favor LFWD or PSTV?

Do insiders and institutionals hold more shares of LFWD or PSTV?

Is LFWD or PSTV more profitable?

Summary

How does Lifeward compare to Cytosorbents?

Which has preferable valuation & earnings, LFWD or CTSO?

Do analysts prefer LFWD or CTSO?

Which has more volatility & risk, LFWD or CTSO?

Does the media refer more to LFWD or CTSO?

Do institutionals and insiders believe in LFWD or CTSO?

Is LFWD or CTSO more profitable?

Summary

How does Lifeward compare to Precision Optics?

Is LFWD or POCI more profitable?

Do institutionals and insiders believe in LFWD or POCI?

Which has preferable valuation & earnings, LFWD or POCI?

Which has more volatility & risk, LFWD or POCI?

Do analysts prefer LFWD or POCI?

Does the media refer more to LFWD or POCI?

Summary

How does Lifeward compare to Star Equity?

Do insiders & institutionals believe in LFWD or STRR?

Does the media refer more to LFWD or STRR?

Do analysts prefer LFWD or STRR?

Which has more risk & volatility, LFWD or STRR?

Is LFWD or STRR more profitable?

Which has better earnings & valuation, LFWD or STRR?

Summary

How does Lifeward compare to NeuroOne Medical Technologies?

Do institutionals & insiders believe in NMTC or LFWD?

Does the media prefer NMTC or LFWD?

Which has more volatility & risk, NMTC or LFWD?

Do analysts recommend NMTC or LFWD?

Is NMTC or LFWD more profitable?

Which has better earnings & valuation, NMTC or LFWD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFWD vs. The Competition

Lifeward Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools